To investigate the relationship between prostate cancer (PCa), presence of metabolic syndrome (MetS), and late-onset hypogonadism (LOH).
Materials and Methods:
One hundred seventy patients who underwent transrectal ultrasonography–guided prostate needle biopsy were included in this study. For the diagnosis of MetS, American Heart Association/National Heart, Lung, and Blood Institute criteria were used. For the diagnosis of LOH, Androgen Deficiency in Aging Males questionnaire and serum total and free testosterone levels were used. Patients were divided into 4 groups according to the presence of MetS and LOH: group 1, MetS and LOH; group 2, with MetS but without LOH; group 3, with LOH but without MetS; and group 4, with neither MetS nor LOH.
The mean age of the patients was 63.7 ± 7.2 years. In group 1, 12 patients (37.5%); in group 2, 5 patients (25%); in group 3, 11 patients (26.8%); and in group 4, 14 patients (18.2%) were diagnosed with PCa. Aggressive PCa was determined in 7 patients in group 1 (21.9%), 2 patients in group 2 (10%), 5 patients in group 3 (12.2%), and 5 patients in group 4 (6.5%). There was a statistically significant difference only in between groups 1 and 4 in terms of detection of PCa (37.5% vs 18.2%, P = .031) and aggressive PCa (21.9% vs 6.5%, P = .019).
These results highlight the fact that coexistence of MetS and LOH increases the risk of PCa and aggressive PCa.